Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28783812.
- Also identified by DOI 10.1001/jamainternmed.2017.3143 and PMC identifier 5818836.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This data analysis simulates the annual price of evolocumab under the outcome-based contracts proposed by Amgen and puts estimates in the context of the available evidence on the cost-effectiveness of PCSK9 inhibitors.
Medical subject headings
- Drug Costs
- Drug Industry
- PCSK9 Inhibitors